Drug Trial Radar · NCT04532606
Impact of Remimazolam on Prognosis After Bladder Cancer Surgery
Last checked: Nov 20, 2026Latest source record: Jul 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,128
Planned (sponsor's estimate)
Start
Feb 5, 2021
Primary completion
Oct 2025
Study completion Oct 2026
Sponsor
- Lead sponsor
- Peking University First HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Beijing Tsinghua Chang Gung Hospital; Navy General Hospital, Beijing; Guizhou Provincial People's Hospital; Jiangsu Provincial People's Hospital; Shanghai 10th People's Hospital
- First posted
- Aug 31, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Bladder cancer is one of the most common genitourinary cancers. Transurethral resection of bladder tumor (TURBT) is the standard therapy for nonmuscle invasive bladder cancer. However, patients after TURBT are at risk for recurrence and progression. Benzodiazepines are proved to inhibit proliferation of multiple types of cancer cells in vitro. Delirium is an acute onset and transient cerebral dysfunction and is associated with worse outcomes. Previous studies indicated that benzodiazepines increase incidence of postoperative delirium. Remimazolam is a new benzodiazepine with rapid onset and ultra-short activity. The aims of this study are to explore the impact of remimazolam for general anesthesia on emergency delirium and recurrence-free survival in patients undergoing bladder cancer surgery.
Conditions
- Benzodiazepines
- Bladder Cancer
- Delirium
- Surgery
- Cancer Recurrence
Interventions
RemimazolamDrug
Remimazolam is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane inhalation is provided when considered necessary.
PropofolDrug
Propofol is administered intravenously for anesthesia induction and maintenance. The dose and infusion rate is adjusted to maintain BIS value between 40 and 60. Analgesia is maintained with remifentanil and/or sufentanil. Muscle relaxation is maintained with rocuronium and/or cisatracurium. Sevoflurane is provided when considered necessary.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of emergence delirium (early).Time frame: Up to 2 hours during the stay in post-anesthesia care unit after surgery.
- Recurrence-free survival (long-term).Time frame: Up to 3 years after surgery.
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Beijing Tsinghua Chang Gung Hospital
Beijing, Beijing Municipality, China · Recruiting
The Sixth Medical Center of PLA General Hospital
Beijing, Beijing Municipality, China · Recruiting
Peking University First Hospital
Beijin, Bejing, China · Recruiting
Guizhou Provincial People's Hospital
Guiyang, Guizhou, China · Recruiting
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China · Recruiting
Shanghai 10th People's Hospital
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.